https://doi.org/10.55788/31402fb2
E-cigarettes have become increasingly popular, especially among youngsters. “This is definitely a worrisome observation,” stated Dr Anu Linnansaari (University of Tampere, Finland). “Exposure to nicotine in adolescence can induce significant long-term deficits in the developing brain with an increased risk of impulsive behaviour, decreased attention, cognitive impairment, and a negative emotional state. Also, this may impose 3 times increased risk of smoking initiation.”
Dr Linnansaari investigated the use and social context of vaping among Danish, Finnish, and Norwegian adolescents aged 15–20 years. Four separate themes were addressed to gain more insights into this practice. The first theme was youth vaping as a social practice, which demonstrated that vaping among youngsters stood as an inherently social practice that was commonly interlinked with experimental and occasional use patterns. Investigating the second theme, appeal of low harm to health, showed that e-cigarettes were perceived as rather harmless, or at least less harmful than ordinary cigarettes and snuff. Occasional use and the so-called ‘innocent’ flavour additives added to this perception. From the appeal of product innovation, the third theme, it was made clear that innovative features facilitated new and playful use practices, again with the novelty and appeal of flavours playing a key role. Finally, the fourth theme, youths' digital lives offering new arenas for e-cigarettes, demonstrated that the use of e-cigarettes by youngsters was integrated into their digital lives. This is mainly encouraged by various social media channels, digital promotion, and availability as well as self-presentation of youngsters on digital platforms. Dr Linnansaari concluded that “considering youth culture, the innovative characteristics of the products, and the global phenomenon of the tobacco epidemic, it is vital to ensure effective tobacco prevention (including awareness) and healthcare practices such as cessation support [1].”
- Linnansaari A. E-cigarette use in Nordic adolescents: trends, youth’s own reflections and cross-country differences in legislation. Results from the NADNIC study. Nordic Lung Congress 2022, 01–03 June, Copenhagen, Denmark.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Sarcoidosis guidelines update Next Article
Effects of passive vaping in COPD patients »
« Sarcoidosis guidelines update Next Article
Effects of passive vaping in COPD patients »
Table of Contents: NLC 2022
Featured articles
Respiratory Disease and Physical Activity
Physical activity improves asthma control
Exercise training for IPF patients is feasible but access needs to be improved
Respiratory Disease and Reproduction
PRO-ART study: unravelling the link between asthma and subfertility
Early-onset and uncontrolled asthma: strong association with recurrent pregnancy loss
Palliative Care in Respiratory Diseases
Advance care planning
Biologics in Asthma
Treatable Traits in Obstructive Airway Diseases
Targeting treatable traits allows a personalised approach to management of (severe) asthma
Bronchiectasis
Challenges in Upper Airway Diseases
Exercise-induced laryngeal obstruction (EILO) is often misdiagnosed
The ULANC Group: working together in CRSwNP/asthma
Interstitial Lung Diseases (ILD)
Rheumatoid arthritis-associated ILD
Thoracic ultrasound: a new diagnostic imaging tool in RA-ILD?
Update on treatment of fibrotic ILD
Respiratory Failure
Lung Cancer Screening in the Nordics
Points of interest for radiologists screening for lung cancer
E-cigarettes
E-cigarettes impose detrimental effects on health
Effects of passive vaping in COPD patients
Vaping amongst adolescents: an alarming trend
Tuberculosis and Sarcoidosis
Detection of latent TB infection key to preventing the spread of the disease
Related Articles
August 17, 2022
Fatigue syndrome in sarcoidosis
August 17, 2022
New antigens in sarcoidosis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com